Abivax S.A.(ABVX)

$114.79—Stale · unknown oldEarnings · Sep 21

Ask SA Chart

Abivax S.A.(ABVX)

NASDAQ • Last print unknown ago

$114.79—Stale · unknown oldEarnings · Sep 21

Ask SA Chart Studio

ABVX(ABVX)

ABVX

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.96

Sep 21, 2026 · Reports after close

Revenue Estimate

$778,451

FY2028E EPS$0.41

FY2029E EPS$6.53

Analyst Sentiment

Wall St. Consensus

Buy

13 analysts·Moderate coverage

Score

12 Buy (92%)1 Hold (8%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

1292%

Hold

18%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$90.00

-21.6%

Consensus

$158.00

+37.6%

Bull

$180.00

+56.8%

12-Month Target Range13 analysts

$90.00$158.00$180.00

Current $114.79Consensus

Current Price

$114.79

Upside to Consensus

$43.21

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+2673.17%

EPS—

FY2028

Rev+379.62%

EPS—

FY2029

Rev+146.76%

EPS+1506.69%

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$4M	$105M	$506M	$1.25B	$1.64B
Low	$2M	$18M	$219M	$499M	$655M
High	$8M	$193M	$1.31B	$3.11B	$4.08B
EBITDA Avg	$-210M	$-166M	$9M	$593M	$758M
Low	$-248M	$-296M	$-6M	$145M	$181M
High	$-172M	$-123M	$186M	$1.70B	$2.19B
EBIT Avg	$-211M	$-167M	$9M	$593M	$758M
Low	$-248M	$-297M	$-7M	$144M	$181M
High	$-173M	$-124M	$186M	$1.70B	$2.19B
Net Income Avg	$-229M	$-185M	$-10M	$454M	$584M
Low	$-267M	$-315M	$-25M	$100M	$128M
High	$-191M	$-142M	$132M	$1.33B	$1.71B
EPS Avg	$-3.30	$-3.06	$0.41	$6.53	$8.41
Low	$-3.84	$-4.53	$-0.36	$1.43	$1.84
High	$-2.75	$-2.05	$1.90	$19.15	$24.66
Analysts (Rev / EPS)	10 / 4	10 / 4	11 / 3	5 / 1	5 / 1

Quarterly

Metric	Q4 2026	Q2 2027	Q4 2027	Q2 2028	Q4 2028	Q2 2029	Q4 2029
Revenue Avg	$792,864	$792,864	$3M	—	—	—	—
Low	$792,864	$792,864	$3M	—	—	—	—
High	$792,864	$792,864	$3M	—	—	—	—
EBITDA Avg	$-50M	$-56M	$-77M	—	—	—	—
Low	$-68M	$-56M	$-77M	—	—	—	—
High	$-33M	$-56M	$-77M	—	—	—	—
EBIT Avg	$-51M	$-56M	$-78M	—	—	—	—
Low	$-68M	$-56M	$-78M	—	—	—	—
High	$-34M	$-56M	$-78M	—	—	—	—
Net Income Avg	$-58M	$-64M	$-85M	$-106M	$-105M	$-102M	$-98M
Low	$-76M	$-64M	$-85M	$-106M	$-105M	$-102M	$-98M
High	$-42M	$-64M	$-85M	$-106M	$-105M	$-102M	$-98M
EPS Avg	$-0.84	$-0.92	$-1.23	$-1.52	$-1.51	$-1.47	$-1.41
Low	$-1.10	$-0.92	$-1.23	$-1.52	$-1.51	$-1.47	$-1.41
High	$-0.60	$-0.92	$-1.23	$-1.52	$-1.51	$-1.47	$-1.41
Analysts (Rev / EPS)	5 / 3	4 / 1	2 / 1	— / 2	— / 1	— / 1	— / 1

Earnings Surprises

Recent Analyst Actions

Jul 24, 2026Morgan Stanley

Abivax price target raised to $180 from $132 at Morgan Stanley

Target:$180.00

+39.9%from $128.63

Jul 9, 2026Piper Sandler

Abivax price target raised to $175 from $165 at Piper Sandler

Target:$175.00

+26.3%from $138.54

Jul 2, 2026Truist Financial

Abivax price target raised to $155 from $135 at Truist

Target:$155.00

+16.9%from $132.56

Jun 30, 2026Jefferies

Abivax upgraded to Buy from Hold at Jefferies

Target:$158.00

+18.6%from $133.26

Jun 30, 2026BTIG

Abivax (ABVX) PT Raised to $175 at BTIG

Target:$175.00

+82.0%from $96.15

Jun 3, 2026Wolfe Research

Abivax price target lowered to $136 from $176 at Wolfe Research

Target:$136.00

+51.6%from $89.72

Jun 2, 2026Truist Financial

Abivax price target lowered to $135 from $140 at Truist

Target:$135.00

+73.5%from $77.82

Jun 2, 2026Morgan Stanley

Abivax price target lowered to $132 from $145 at Morgan Stanley

Target:$132.00

+1.8%from $129.69

Jun 2, 2026Wedbush

Wedbush upgrades Abivax to Neutral, lowers target to $90

Target:$90.00

-30.6%from $129.69

Jun 2, 2026Jefferies

Jefferies Downgrades Abivax (ABVX) to Hold

Target:$90.00

-30.6%from $129.69

Feb 24, 2026Wedbush

Abivax initiated with a Neutral at Wedbush

Target:$110.00

-17.2%from $132.91

Jan 9, 2026Morgan Stanley

Abivax price target raised to $145 from $101 at Morgan Stanley

Target:$145.00

+24.0%from $116.97

Jan 8, 2026BTIG

Abivax price target raised to $150 from $120 at BTIG

Target:$150.00

+18.6%from $126.48

Jan 8, 2026Oppenheimer

Abivax (ABVX) Reiterated at Market Outperform by Citizens: Has Cash Runway into 4Q27

Target:$131.00

+3.6%from $126.48

Dec 18, 2025Guggenheim

Abivax price target raised to $175 from $150 at Guggenheim

Target:$175.00

+49.3%from $117.23

Dec 16, 2025Piper Sandler

Abivax price target raised to $142 from $112 at Piper Sandler

Target:$142.00

+28.0%from $110.98

Nov 24, 2025Truist Financial

Abivax initiated with a Buy at Truist

Target:$140.00

+17.5%from $119.12

Nov 5, 2025Wolfe Research

Abivax initiated with an Outperform at Wolfe Research

Target:$176.00

+76.7%from $99.61

Oct 13, 2025Barclays

Abivax initiated with an Overweight at Barclays

Target:$142.00

+51.4%from $93.77

Oct 10, 2025Guggenheim

Abivax price target raised, named a 'Best Idea' at Guggenheim

Target:$150.00

+65.5%from $90.61

Oct 6, 2025BTIG

Abivax price target raised to $120 from $112 at BTIG

Target:$120.00

+38.5%from $86.67

Sep 25, 2025JMP Securities

Abivax price target raised to $114 from $95 at Citizens JMP

Target:$114.00

+39.0%from $82.00

Jul 23, 2025Leerink Partners

Abivax (ABVX) PT Raised to $74 at Leerink Partners

Target:$74.00

+16.1%from $63.74

Jul 18, 2025JMP Securities

Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)

Target:$33.00

+219.1%from $10.34

Mar 20, 2025Morgan Stanley

Abivax assumed with an Equal Weight at Morgan Stanley

Target:$12.00

+70.0%from $7.06

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance